Dear National Comprehensive Cancer Network Central Nervous System Panel:

We write to request that the National Comprehensive Cancer Network (NCCN) expedite review of Novocure’s NovoTFF-100A system (now “Optune”) to determine whether there is sufficient evidence and agreement to declare it appropriate for the treatment of newly diagnosed and recurrent glioblastoma patients.

On November 15, 2014, at the Society for Neuro-Oncology annual meeting, Dr. Roger Stupp presented the phase III clinical trial data regarding Optune in combination with standard of care temozolomide for newly diagnosed glioblastoma patients. Dr. Stupp reported that patients who received the combination of Optune along with temozolomide survived approximately three months longer than those who received temozolomide alone. The trial’s Independent Data Monitoring Committee recommended the trial be discontinued due to the promising nature of the results. The final data is under review for publication and we await further guidance from the FDA.

Based on what we do know so far, we understand that Optune is considered safe for the treatment of glioblastoma. In addition, the device, in combination with temozolomide, has demonstrated (prior to the publication of research results) effectiveness above the current standard of care. In light of the short survival times for patients with glioblastoma, it is important that treatments that demonstrate safety and effectiveness be made available to patients as rapidly as possible.

Accordingly, we request that NCCN expedite its review of the Optune trial results and make a determination regarding appropriateness as soon as possible. Thank you for your consideration.

Sincerely,

Max Wallace